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 A solution was developed to construct fusion proteins of Hepatitis B virus
core protein in which the functions of the fused domains were kept.
 The  solution contains  two principles:  (1)  fuse heterogeneous proteins at
the N terminus of HBc; (2) use long Glysine‐serine linkers between the two
domains.
 EGFP‐HBc and RFP‐HBc constructed following the principles supported the
formation of nucleocapsid in HepG2 cells.
Abstract 
Fusion core proteins of Hepatitis B virus can be used to study core protein 
functions or capsid trafficking. A problem in constructing fusion core proteins 
is functional impairment of the individual domains in these fusion proteins, 
might due to structural interference. We reported a method to construct fusion 
proteins of Hepatitis B virus core protein (HBc) in which the functions of fused 
domains were partially kept. This method follows two principles: (1) fuse 
heterogeneous proteins at the N terminus of HBc; (2) use long Glysine-serine 
linkers between the two domains. Using EGFP and RFP as examples, we 
showed that long flexible G4S linkers can effectively separate the two domains 
in function. Among these fusion proteins constructed, GFP-G4S186-HBc and 
RFP-G4S47-HBc showed the best efficiency in rescuing the replication of an 
HBV replicon deficient in the core protein expression，though both of the two 
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fusion proteins failed to support the formation of the relaxed circular DNA. 
These fluorescent protein-tagged HBcs might help study related to HBc or 
capsids tracking in cells. 
Keywords: Hepatitis B virus; core protein; engineering; fusion proteins. 
Introduction 
Hepatitis B virus (HBV) is an enveloped virus which packages its DNA 
genome in an inner icosahedra capsid. The capsids are built with core proteins 
(HBc), which are 183-185 amino acid residues long. According to the function, 
HBc can be divided into two domains: the assembly domain (amino acid 
residues 1-140, Fig. 1A) which is necessary and sufficient to form dimers, and 
the carboxy-terminal domain (CTD) (residues 150–183, Fig. 1A) which has a 
high affinity for RNA(Porterfield et al., 2010) and is needed for pgRNA 
encapsidation (Nassal, 1992). By providing a functional room for genome DNA 
replication, the capsids apparently are indispensable for the fulfillment of HBV 
life cycle (for reviews, see (Seeger and Mason, 2000, Nassal and Schaller, 1993, 
Seeger and Mason, 2015)).  
Structure of HBV capsid has been studied extensively by both cryo-EM 
and X-ray crystallography (Bottcher et al., 1997, Crowther et al., 1994, Wynne 
et al., 1999, Dryden et al., 2006, Conway et al., 1997). Bacterially expressed 
core proteins spontaneously assemble into two types of capsids, resembling the 
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native capsids morphologically(Dryden et al., 2006), composed of 180 or 240 
core proteins arranged with T = 3 or T = 4 icosahedral symmetry, respectively 
(Bottcher et al., 1997, Conway et al., 1997, Crowther et al., 1994, Wynne et al., 
1999). The dimeric spikes formed by 4-helix bundles protrude from the surface 
of capsids. At the tips of the spikes are the major immunodominant region 
(MIR) of the HBc molecule presented by amino acids 78–82 (Bottcher et al., 
1997, Wynne et al., 1999; Fig. 1A). The two N termini per dimer were located 
on either side of the spike-stem, at the level at which it enters the shell 
(Conway et al., 1998), and the C termini lines the capsid interior (Zlotnick et al., 
1997, Wang et al., 2012; Fig. 1A). 
Fusion core proteins have been exploited to study core protein functions. 
Green fluorescent protein (GFP) is usually fused with HBc to facilitate 
observation. Schaller’s lab used an N-terminally fused GFP-HBc to investigate 
the factors influencing the intracellular distribution of HBc (Weigand et al., 
2010). The same lab used a line of N-terminally fused GFP-DHBcs to identify 
the nuclear localization signal that mediates nuclear pore association of the 
duck hepatitis B virus nucleocapsid (Mabit et al., 2001). A COOH-terminally 
truncated core protein with GFP inserted into the immunodominant loop 
(amino acids 78–83) (Kratz et al., 1999) has been used to investigate the 
interaction of hepatitis B virus capsids with nuclear pore complexes in 
permeabilized HeLa cells (Lill et al., 2006).  
The above studies using GFP-HBc fusion proteins provided much helpful 
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information about the biological features of HBc. However, whether these 
fusion proteins keep the authentic functions of HBc is not so clear. One fact is 
that the N-terminally fused GFP-HBc is unable to form capsids (Weigand et al., 
2010). Although the core protein with GFP inserted into the immunodominant 
loop did allow capsids formation (Kratz et al., 1999, Lill et al., 2006), our 
results showed that this fusion protein did not support HBV DNA replication in 
HepG2 cells (Chen et al., 2013). These data indicated that the functions of HBc 
were not fully kept in these GFP-HBcs, might attributable to the structural 
interference between the two proteins fused together. A core fusion protein fails 
to keep the functions of the core domain means that the core domain has been 
different from the wild type. Thus, studying core protein using this kind of core 
fusion proteins might be unsuitable in cases requiring a highly functional core 
domain. Here, we reported a solution for the problem of functional interference 
on HBc imposed by the specific foreign proteins in fusion proteins. This 
solution contains two key points: (i) fuse the foreign proteins at the N terminus 
of HBC; (ii) use long flexible linkers between the two proteins to be fused.  
Materials and Methods 
Plasmids.  
HBV1.1c- was constructed previously, in which the 40th amino acid of 
core protein was mutated to a stop codon (GAA to TAA) (Chen et al., 2013). 
WtHBc expresses wild type HBc of genotype D (Chen et al., 2013) derived 
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from plasmid PCH9/3091 (Nassal, 1992). G-C12-HBc expresses the HBc with 
the extra 12 amino acids (Fig 1, B) from HBc of genotype G inserted between 
its 2nd and 3rd amino acid. To construct G-C12-HBc, a fragment was amplified 
from WtHBc with primers F G12 and Rc456. The 5’ end of F G12 carried a 
sequence that can anneal to the sequence immediately upstream of the 2nd 
codon of the HBc gene on WtHBc. Primer Rc456 can anneal to the sequence in 
the HBc gene (nt434-456). This fragment was used to replace the 
corresponding HBc gene region by Fragment Substitution Reaction (FSR) 
method developed previously (Hu et al., 2012). Briefly, a FSR system of 20μl 
was constructed which contained 200ng fragment F G12+ Rc456, 10ng 
plasmid WtHBc, 10μl PrimeStar HS 2×premix (Takara) and H2O. The reaction 
was performed on a PCR instrument under following condition: Initial 
denaturation at 94oC for 3 min, followed by 18 cycles of denaturation at 94oC 
for 15 sec, annealing at 55oC for 15 sec, and extension at 72 oC for 3 min. The 
resultant FSR product was purified with a PCR Purification Kit (Roche 
Diagnostics), digested with Dpn I (Promega, Madison, WI), and then 
transformed into competent JM109 cells. The clone contained the replaced 
fragment was confirmed by sequencing. 4×G-C12-HBc is the same as 
G-C12-HBc except that it contains 3 copies more G-C12 at the N terminus of
HBc. To construct G-C12-HBc, a fragment was first amplified from 
G-C12-HBC with primers F4G3 and R1798. This fragment was amplified with
primer F4G2 and Rc456, and the resulting fragment was then amplified with 
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primers F4G1 and Rc456. The last fragment was used to replace the 
corresponding region on G-C12-HBc by FSR method. G4S12-HBc is a plasmid 
that expresses the HBc with a 12 amino acid residues-long Glycine-Serine 
linker (GSG4SG4S) at its N terminus. To construct G4S12-HBc, the fragment 
amplified from WtHBc with primers F G4S12 and R1798 was replaced to 
WtHBc by FSR method. G4S47-HBc, G4S92-HBc, and G4S186-HBc are the 
same as G4S12-HBc except that longer Glycine-Serine linkers were added to 
the N terminus of HBc respectively. To construct G4S47-HBc (G4S47 means a 
linker with a length of 47 amino acids, and the sequence of which was 
presented in Fig. 1B), a fragment was amplified first from G4S12-HBc with 
primers F47gly 2 and R1798, and this fragment was used as template to 
amplify a fragment with primers F47gly 1 and Rc456. The last fragment was 
then replaced to WtHBc by FSR method. To construct G4S92-HBc, primers F 
BsmBI1 and R BsmBI1were used to amplify the fragment 1 (frag1) from 
G4S47-HBc. Primers F BsmBI2 and R BsmBI2 were used to amplify the 
fragment 2 (frag2) from G4S47-HBc. Primers F BsmBI vect and R BsmBI vect 
were used to amplify the fragment vector (vector) from WtHBc. The above 
three fragments were ligated together by Golden gate method (Engler et al., 
2009, Engler et al., 2008, Weber et al., 2011). Specifically, a 10μl Golden gate 
system was constructed which contained 20ng of the fragment each, 0.75μl 
BsmB I (NEB), 1μl DTT (10mM), 0.25μl T7 ligase (NEB), 1μl ATP (10mM), 
1μl Tango buffer (Fermentas) and H2O. Reaction parameters: 37oC for 5 min, 
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22 oC for 5 min, 25 cycles. The resultant product was transformed into 
competent JM109 cells. The right clones were confirmed by sequencing. To 
construct G4S186-HBc, the 4 fragments were amplified respectively from 
G4S47-HBc using primer pairs F BsmBI1 + R BsmBI1, F BsmBI2 + R BsmBIa, 
F BsmBI1b + R BsmBI1b, and F BsmBIc + R BsmBI2. These 4 fragments 
were ligated with the fragment vector (the same as the fragment vector above) 
by Golden gate method. To construct GFP-G4S47-HBc，GFP-G4S92-HBc and 
GFP-G4S186-HBc, the EGFP fragment amplified from pEGFP-N1 with 
primers FGFP-HBC and RGFP-HBC was replaced to G4S186-HBc by FSR. 
There are 4 possible annealing sites between the fragments and the 
glycine-serine clustered repeat sequence on G4S186-HBc. FSR product after 
Dpn I digestion was transformed, and three GFP-HBc constructs with G4S47, 
G4S92 and G4S186 linkers were obtained by clone screening and sequencing. 
Similarily, to construct RFP-G4S47-HBc and RFP-G4S186-HBc, the RFP 
fragment amplified from pAD-RFP (kindly provided by Dr. TongChuan He) 
with primers FRFP-HBC and RRFP-HBC was replaced to G4S186-HBc. Two 
RFP-HBC constructs with G4S47 and G4S186 linkers were obtained by clone 
screening. All the sequences of the primers used are listed in table 1. 
Cell culture and transfection 
HepG2 cells were grown at 37 °C under 5% CO2 in modified Eagle’s 
medium supplemented with 10% (v/v) fetal bovine serum. For transfection, the 
cells were seeded into six-well plates and allowed to adhere overnight. On the 
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following day, when the cells were 60%–70% confluent, the culture medium 
was replaced with fresh medium and 4 g of HBV construct was transfected 
into the cells in each well using 8 L Lipofectamine 2000 (Invitrogen), 
according to the instructions provided by the supplier. The culture medium was 
changed every 2 days, and the cells were harvested on day 5 after transfection. 
Western blot analysis.  
Cell lysis samples resolved on 10% SDS-PAGE gels were transferred onto 
PVDF membranes (Millipore). The membranes were blocked with 5% skim 
milk powder and probed with specific primary antibodies against GFP (Origen), 
RFP (Abcam) and GAPDH (Beyotime), respectively. Bound antibody was 
revealed with secondary antibodies conjugated with HRP and the 
chemiluminescent substrate ECLplus (Amersham Pharmacia), and then 
visualized by Fusion Fx5 system (Vilber Lourmat). 
Viral DNA analysis 
Intracellular viral core DNA was extracted as following. Cells from one 
well of a 6-well plate were lysed with 400μl of lysis buffer containing 10 mM 
Tris-HCl (pH 8.0), 1 mM EDTA, 1% NP-40 at room temperature for 30 min. 
Cell debris and nuclei were removed by centrifugation, and the supernatant was 
mixed with 3μl of 1 M MgCl2 and DNase I (Promega; added to 40 U/ml) to 
digest the contaminating plasmid. After 3 hr at 37 oC, the reaction was 
terminated with 10 mM EDTA, and then 140 ml of 35% polyethylene glycol 
(PEG) 8000 containing 1.5 M NaCl was added. After incubation for 1 hr on ice, 
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the viral nucleocapsids were pelleted by centrifugation at 11,000g for 5 min at 
4 oC, and then digested (3 hr at 45 oC) in 400 μl of buffer containing 1 mg/ml 
proteinase K (Promega). The digestion mixture was extracted twice with 
phenol. The DNA was precipitated with ethanol and dissolved in TE buffer (10 
mM Tris–HCl [pH 8.0], 1 mM EDTA). For southern blot, DNA samples were 
resolved in 1% argarose gels and transferred to positively charged nylon 
membranes (Roche). Hybridization and detection were performed with DIG 
DNA Labeling and Detection Kit (Roche), according to the manufacturer’s 
instructions.  
Viral RNA analysis 
Trizol reagent (Life technologies, Carlsbad, USA) was used to extract 
total RNA according to the manufacturer’s instructions. Encapsidated RNA was 
extracted as previously described (Guo et al., 2003, Mao et al., 2013) with 
modifications. Briefly, cells in a well of a 12 well-plate were lysed with 250μl 
of lysis buffer containing 10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 1% 
NP-40 at room temperature for 30 min. Cell debris and nuclei were removed by 
centrifugation, and the supernatant was mixed with 1.5μl of 1 M CaCl2 and 
10U micrococcal nuclease (NEB) to digest the unprotected RNA for 15min at 
37 oC. Add 6μl of 0.5M EDTA to stop the reaction. Then 750μl of Trizol LS 
(Life technologies) was used to extract the encapsidated pgRNA according to 
the manufacturer’s instructions. For Northern blot, 5μg of total RNA of each 
sample or encapsidated pgRNA from each well was separated on a 1.2% 
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agarose gel containing 2% formaldehyde and then transferred to a positively 
charged nylon membrane (Roche Diagnostics). HBV RNA was detected by a 
digoxigenin labeled RNA probe prepared by DIG Northern Starter Kit (Roche 
Diagnostics) according to the manufacturer’s instructions. The template for 
RNA probe preparation was the 0.7kb fragment amplified from PCH9/3091 
using primers F1085 and R1798 T7. 
Core particle analysis. 
Intracellular HBV capsids and associated viral DNA were analyzed as 
described previously (Guo et al., 2006, Guo et al., 2007, Xu et al., 2010). 
Briefly, cells in each well of a 6-well plate were lysed by 400 μl buffer 
containing 10 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA, and 0.1% 
NP-40. Cell debris was removed by centrifugation at 12,000 × g for 5 min. 
Twenty microliters of the clarified cell lysates were resolved on nondenaturing 
1% agarose gels and transferred to nitrocellulose filters by blotting with TNE 
buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 1 mM EDTA). HBV 
capsids were detected by probing the membrane with the antibody against the 
HBV core protein or against GFP mentioned above. Bound antibody was 
revealed by HRP-conjugated secondary antibodies and the chemiluminescent 
substrate ECLplus, and then visualized by Fusion Fx5 system. To detect 
capsid-associated HBV DNA, the membranes were treated with buffer 
containing 0.5 N NaOH and 1.5 M NaCl for 5 min, followed by neutralization 
with buffer containing 1 M Tris-HCl and 1.5 M NaCl for 5 min. The viral DNA 
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was detected with DIG DNA Labeling and Detection Kit, according to the 
manufacturer’s instructions. For extracellular capsids assay, 600μl of 35% 
PEG8000 was added to 2ml of culture medium. Stand the mixture overnight at 
4 oC after rotating for 30min. Capsids were then precipitated by centrifugation 
with 10,000g for 5min. The pellet was dissolved with 20μl TNE buffer and 
applied to native agarose gel assay as described above. 
Immunofluorescence Assay 
Cells on glass coverslips were fixed with 2% paraformaldehyde in PBS, 
and 0.1% Triton-X100 was used to permeabilize cell membrane for 1hr. 
Samples were then blocked for 1hr with blocking buffer (10%FBS and 2%BSA 
in PBS). For HBc detection, the cells were incubated with the DAKO rabbit 
polyclonal antibody (1/500 in the blocking buffer) for 1.5hr. After rinsing with 
PBS 3 times, the cells were incubated with the secondary antibody (Alex Fluro 
594 goat anti rabbit antibody, Life technologies) and DAPI (Thermo Fisher 
Scientific) for 1hr. For fluorescent protein detection, only DAPI was used. The 
confocal images were collected with the Leica DMi8 confocal microscope 
through a 40× objective.  
Results 
The N terminus of core protein tolerates modification 
To keep the function of HBc in a fusion protein, we first considered the 
fusion sites. As mentioned above, heterogenous peptides or proteins have been 
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linked to 3 sites, i.e. N terminus, C terminus and MIR, of HBc, resulting in 
fusion proteins that can form capsids (Roose et al., 2013). We chose the N 
terminus of HBc as our modification target based on the following reasons: (1) 
We speculated that a protein fused to the C terminus of authentic HBc might 
interfere the function of CTD, and in turn the package of pgRNA, since the C 
terminus lines the capsid interior (Fig. 1A). (2) Our previous results showed 
that the HBc with GFP inserted in MIR did not support HBV DNA replication 
in HepG2 cells (Chen et al., 2013). (3) HBc of genotype G HBV has an extra 
12 amino acid residues at its N terminus, in contrast to other genotypes 
(Fig.1B). This extra 36 nucleotide sequence had been shown to increase core 
protein at the level of translation, and do not influence genome maturity when 
introduced into genotype A and D clones (Li et al., 2007). This implies that the 
N terminus of HBc might tolerate modification. (4) The polymerase in the 
nucleocapsids formed by the HBc with an extra 23 amino acid residues at the N 
terminus did presented endogenous polymerase activity, though this modified 
HBc supported HBV DNA replication less efficiently then wild type in 
hepatoma cells (Hui et al., 1999).  
The next thing to be considered was the type and length of linker. A linker 
serves as a separator to decrease the interference between the two proteins 
fused. We tested 2 types of linkers. One is the extra 12-residues presented in 
the N terminus of genotype G HBc. The reason we chose this peptide is that it’s 
a naturally evolved sequence, and do not influence HBV replication when 
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introduced into the HBc of genotype A and D (Li et al., 2007). The other one 
tested is the usually used Glycine-Serine flexible linker.  
 We tested the function of the HBcs fused different linkers alone at their N 
terminus. Replication rescue experiment was conducted to test the function of 
modified HBcs. The plasmids expressing different HBcs were co-transfected 
respectively with HBV1.1c-, a plasmid expressing all other components 
required for HBV DNA replication except for HBc. The replication of HBV 
DNA will be rescued if a functional HBc is provided. As shown in Fig.1 D, 
G-C12-HBc rescued HBV DNA replication while 4×G-C12-HBc not,
suggesting that extended G-C12 peptide (Fig. 1C) do not obstruct the function 
of core protein significantly but 4×G-C12 (Fig. 1C) do. Specifically, no pgRNA 
was encapsidated in the 4×G-C12-HBc co-transfection experiment (Fig.1D, 
lower panel). Co-transfection of G4S12-c and G4S47-c with HBV1.1c- 
confirmed that both rescued HBV DNA replication well (Fig. 1D), and the 
G4S47-c even supported replication better than WtHBc (Fig.1D). More 
encapsidated pgRNA was detected in the G4S47-c transfection samples 
(Fig.1D). This result encouraged us to add longer G4S linkers to the N terminus 
of core protein, with the speculation that longer linkers might separate fused 
proteins better. Interestingly, core protein with G4S linkers even longer than 
HBc itself (G4S186-HBc) in length supported HBV DNA replication (Fig.1D), 
indicating these linkers themselves do not disrupt HBC function.  
GFP-HBc with long GS linkers keeps the functions of individual domains. 
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We further tested whether those long GS linkers described above can serve 
as effective “separators” to keep functions of the 2 individual domains in an 
HBc fusion protein. We constructed plasmids expressing the fusion protein 
EGFP-HBcs. The EGFP fragment amplified from pEGFP-N1 was cloned into 
the plasmid G4S186-HBc by Fragment Substitution Reaction (FSR) method 
developed previously (Fig. 2 A and reference (Hu et al., 2012)). One end of the 
EGFP fragment can anneal to the immediate upstream of the G4S186, and the 
other end can anneal to one of the 4 possible sites (because G4S186 is roughly 
4×G4S47. Fig. 2A). Among the picked clones after transformation of FSR 
product, we identified 3 constructs of GFP-G4S47-HBc, GFP-G4S92-HBc and 
GFP-G4S186-HBc by sequencing. These three clones correspond respectively 
to the molecules produced by annealing of the EGFP fragment to the site 1, 2 
and 4 indicated in Fig. 2A.  
Western blotting confirmed the expression of these HBc fusion proteins (Fig. 
2B). To assess the function of these fusion proteins, we transfected these 
constructs into HepG2 cells. Green fluorescence can be easily observed 24h 
after transfection (Fig. 2C), indicating that the function of EGFP was retained 
in all the 3 fusion proteins. Almost all of the green fluorescence (from GFP) 
exactly colocalized with the red fluorescence (from HBc) in the 3 GFP-HBc 
transfection groups, indicating that these fusion proteins were expressed. 
Notably, the fluorescence forms distinct foci. This pattern is different sharply 
from that of the EGFP expressed from plasmid pEGFP-N1 (Fig. 2C), or the 
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GFP-HBc fusion protein reported previously (Weigand et al., 2010), which 
diffused evenly throughout the whole cells. The foci of fluorescence implied 
that these fusion proteins might aggregate themselves together through the 
interaction between core proteins. The WtHBc presented less foci than those 
GFP-HBcs, and distributed more evenly both in the cytoplasm and the nuclei.  
To confirm the particle formation of the GFP-HBc proteins, cytoplasm lysis 
were resolved on native agarose gels after co-transfection of these constructs 
with HBV1.1c- respectively. A GFP antibody and an HBc antibody were used 
to detect capsid-like particle. As shown in Fig 2D, capsid-like particles formed 
by GFP-G4S47-HBc, GFP-G4S92-HBc and GFP-G4S186-HBc can be detected 
with both of the antibodies, while WtHBc core particle can only be detected by 
the HBc antibody. The signals appeared at the same location when using both 
GFP and HBC antibodies suggested that the particles contain the corresponding 
fusion proteins. As expected, the migration velocity was WtHBc > 
GFP-G4S47-HBc > GFP-G4S92-HBc> GFP-G4S186-HBc. To characterize 
these capsid-like particles further, we assayed the particle-associated HBV 
DNA. HBV DNA probe was used to detect HBV DNA in these capsid-like 
particles. As shown in Fig. 2D, only the capsid-like particles formed by 
GFP-G4S186-HBc contained detectable HBV DNA. The same location of HBV 
DNA and the core particles indicated that the DNA was synthesized in the 
capsid-like particles formed by G4S186-HBc. And this kind of capsid-like 
particles must be functional particles resembling wild type capsids. No HBV 
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DNA in GFP-G4S92-HBc particles was detected, probably attributed to its low 
quantity, since the HBV DNA appeared in the extracted cytoplasm DNA, 
though very weak (Fig. 2 F), must be synthesized in functional capsids. In 
conclusion, EGFP-HBc fusion protein linked with G4S186 linker keeps the 
function of both EGFP and HBc well.  
RFP-HBc with long GS linkers keeps the functions of individual domains. 
As another example of HBc fusion protein, RFP gene was inserted at the N 
terminus of HBc linked with G4S47 and G4S186 linkers, using FSR method 
described above (Fig. 3 A). Expression of these two proteins in HepG2 cells 
was confirmed by Western blotting (Fig. 3 B). A line of evidence supported that 
these fusion proteins keep, at least partly, the function of both of the two fused 
domains. (1) The two fusion proteins both emitted red fluorescence when 
transfected into HepG2 cells, while the distribution patterns were somewhat 
different from that of WtHBc (Fig. 3C); (2) Intracellular capsid-like particles 
can be detected both by an RFP and an HBc antibody at the same location (Fig. 
3 D); (3) Intracellular core DNA can be detected when these two constructs 
were co-expressed with HBV1.1c- respectively. RFP-G4S47-HBc supported 
HBV DNA replication better than RFP-G4S186-HBc, implying less 
interference RFP imposed on HBc structure. Noteworthy is that two bands 
were detected of the capsids formed by RFP-G4S186-HBc, implying two kinds 
of capsids formed. Further study is needed to identify whether the lower band 
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represents capsids composed of fewer copies of RFP-G4S186-HBc proteins. 
Capsid DNA was not clearly detected both for RFP-G4S47-HBc and 
RFP-G4S186-HBc, might attributed to their less efficiency to support HBV 
DNA replication compared to the WtHBc (Fig. 3 F).  
We next co-transfected RFP-G4S47-HBc with GFP-G4S186-HBc into 
HepG2 cells, to observe if these 2 proteins colocalize. As shown in Fig 2C, 
these 2 proteins apparently colocalized together, especially in the foci which 
distributed both in the cytoplasm and nuclei. By contrast, in the cells 
co-transfected with RFP and GFP expressing plasmids, both of the 2 proteins 
evenly distributed throughout the cells and no apparent colocalization can be 
observed (Fig. 3C). 
Discussion 
We provided a way to keep the individual function of the proteins being 
fused in an HBc fusion protein. One purpose of constructing fusion proteins is 
to endow a protein with new function, while retaining its original function. 
Unfortunately, the proteins being linked together may interfere with each other 
in many cases. As for HBc, it functions as a building block of capsids, a 
packager of HBV pgRNA and polymerase, and a helper during the synthesis of 
HBV DNA in capsids (for a review, see (Zlotnick et al., 2015)). Keeping one of 
these functions in a fusion protein, like the capacity of capsids formation, may 
be relatively easy to achieve, as demonstrated by the numerous examples for 
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vaccine purpose (Pumpens and Grens, 2001, Roose et al., 2013, Ulrich et al., 
1998). To our knowledge, however, no HBc fusion protein has been reported in 
which more functions of HBc have been successfully kept, except the one with 
an extra 23aa stretch at the N terminus of HBc (Hui et al., 1999). Some of the 
HBc fusion proteins expressed here can form functional capsids. HBV DNA 
replicated in capsids indicated that pgRNA and polymerase have been 
packaged, and they must interact with the capsids appropriately. The retention 
of these functions after the addition of GFP and RFP tags provided us a new 
tool to study the dynamics of HBc or the capsids and the interaction between 
HBcs and themselves and other virus or host factors in cells.  
All of the HBc fusion proteins constructed here formed apparent foci in cells, 
largely in the cytoplasm and less in the nuclei (Fig. 2C and Fig. 3C). WtHBc 
presented foci only in a minor part of the cells in our experiment, and the EGFP 
and RFP did not form this kind of foci (Fig. 2C and Fig. 3C). Possible reason 
for this difference include: (1) the fusion made the original proteins (the 
fluorescent proteins or the HBc) tend to aggregate, forming larger particles than 
a normal capsid which usually contains 240 HBcs. (2) more antibodies bound 
to the capsid like particles formed by the HBc fusion proteins, making these 
particles look like larger than a normal one. We have no evidence to distinguish 
these hypotheses till now, and further studies are warranted to make this clear.  
In addition, co-transfection experiment clearly demonstrated that 
GFP-G4S186-HBc and RFP-G4S47-HBc had an apparent colocalization (Fig. 
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3C). This colocalization cannot be explained by the interaction between GFP 
and RFP, since the co-transfection experiment with GFP and RFP expressing 
plasmids did not show a colocalization of these 2 proteins (Fig. 3C). There 
probably is an interaction between the HBcs in the 2 fusion proteins, 
presumably an interaction between 2 heterogeneous monomers (a 
GFP-G4S186-HBc monomer and a RFP-G4S47-HBc monomer), or that 
between 2 heterogeneous dimers (a GFP-G4S186-HBc dimer and a 
RFP-G4S47-HBc dimer). If this is the case, the colocalized fluorescence would 
be used to reflect the interaction.  
Different linkers have different influence on the function of fusion proteins. 
Although the G-C12 peptide did not disturb the function of HBc, the 4×G-C12 
peptide significantly impaired it. Apparently, 4×G-C12-HBc did not assemble a 
capsid that encapsidate pgRNA (Fig.1C). We did not determine whether this 
kind of fusion protein can form capsids, and how this repeated peptide 
influence the function of HBc is not clear. All these flexible linkers with 
different lengths we tested did not influence the function of HBc significantly. 
A surprising observation is that the HBc added the G4S47 linker supported 
HBV DNA replication better than the wild type. Possible explanations for this 
phenomenon include but not limit to that the nucleocapsids formed by G4S47-c 
may not be enveloped and thus accumulated in cells, or that G4S47-c has a 
higher efficiency to package pgRNA. While the EGFP was fused to HBc, it 
was linker G4S186 but not others that kept the function of HBc best. However, 
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no clear relaxed circular DNA was detected in GFP-G4S186-HBc rescued 
replication (Fig. 2F), indicating a defect in either second-strand DNA synthesis 
or genome circularization still exists. In the case of RFP-HBcs, the one with 
G4S47 linker performed better than that with G4S186 in supporting HBV DNA 
replication. Due to the complicated factors influencing the structure and 
function of a protein, which kinds of linkers to be adopted for the construction 
of other fusion proteins need to be determined empirically.  
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Figure legends. 
Fig. 1, The N terminus of core protein tolerates modification. (A) Structure 
models of HBc monomer and dimer. (B) Alignment of the start part of the 
ORFs of HBc gene of A to H genotype. The sequences are from the whole 
genome of 831 HBV strains retrieved from Genebank(Hu et al., 2009). There is 
an extra 12aa insertion at the N terminus of HBc of genotype G. (C) Amino 
acid sequences added at the N terminus of genotype D HBc. (D) Functional 
assay of core fusion proteins. Plasmids expressing wild type or engineered core 
proteins were co-transfected with HBV1.1c- into HepG2 cells respectively. 
Intracellular core DNA was extracted and detected by Southern blot. Total 
RNA or encapsidated RNA was extracted and detected by Northern blot. RC, 
relaxed circular DNA; DSL, double-strand linear DNA; SS, single-strand DNA. 
pgRNA, pregenomic RNA.  
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Fig. 2, Functional characterization of EGFP-HBcs. (A) Construction of 
EGFP-HBc expressing plasmids. The EGFP fragment was amplified from 
pEGFP-N1 with a pair of primers. At the 5’ end (black bar on the mega primers) 
of the forward primer is a sequence that can anneal to the sequence (black bar 
on the plasmid) just upstream of the G4S186 linker (blue bars), and the 5’ end 
(orange bars on the mega primers) of the reverse primer was designed to anneal 
to the start parts of each of the four G4S47 blocks. The fragment was then used 
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as “mega-primers” to replace the corresponding region on the plasmid 
G4S186-HBc. Theoretically, there would be four kinds of products by 
annealing of the mega-primers to the different positions at the tandem repeat 
G4S region on the template. Actually, three kinds of constructs, i.e. 
GFP-G4S47-HBc, GFP-G4S92-HBc and GFP-G4S186-HBc, were obtained by 
sequencing. (B) Expression of EGFP-HBc fusion proteins in cultured cells. The 
3 plasmids were transfected into HepG2 cells respectively. Western blotting 
was used to detect the expression of the fusion proteins 48h after transfection. 
(C) Intracellular localization by immunofluorescence confocal microscopy. The
cells seeded on glass coverslips were transfected with the different plasmids. 
Twenty-four hours after transfection, the cells were assayed by 
immunofluorescence with the anti-HBc antibody. Nuclei were visualized by 
staining with DAPI. The green fluorescence of these samples was also 
observed. (D) Capsids and capsid-associated DNA assay. The HepG2 cells 
transfected with the 3 plasmids were harvested and lysed 5 days 
post-transfection, and part of the lysis of each sample was resolved by native 
agarose gels electrophoresis. For capsids assay, samples in the gels were 
transferred to an NC membrane, and then detected by using an HBc antibody 
and a GFP antibody. For capsid-associated DNA assay, samples were 
transferred to a nylon membrane, and then hybridized by using an HBV DNA 
probe. (E) HBV RNA assay. Total RNA was extracted from the HepG2 cells 
co-transfected with HBV1.1c- and the plasmids expressing different core 
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proteins. Northern blotting was used to detect HBV RNA. (F) Core DNA assay. 
The 4 plasmids were co-transfected with HBV1.1c- respectively and 
intracellular core DNA was extracted 5 days after transfection. HBV DNA was 
detected by Southern blotting. RC, relaxed circular DNA. SS, single-strand 
DNA. 
Fig. 3 Functional characterization of RFP-HBcs. (A) Construction of the 
RFP-HBc vectors. RFP gene was amplified from pAD-RFP and was used as 
“mega-primers” to replace the corresponding region on the plasmid 
G4S186-HBc by FSR. There should be four annealing positions between the 
“mega-primer” and the tandem repeat region on the template. Two kinds of 
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constructs, i.e. RFP-G4S47-HBc and RFP-G4S186-HBc, were identified by 
sequencing. (B) Expression of RFP-HBcs in cells. HepG2 cells transfected with 
the 2 plasmids were assayed by Western blotting to confirm the expression of 
the fusion proteins. (C) Intracellular localization by immunofluorescence 
confocal microscopy. The cells transfected with different plasmids were 
assayed by immunofluorescence with the anti-HBc antibody (no antibody was 
used for the detection of fluorescent proteins). Nuclei were visualized by 
staining with DAPI. (D) Capsids and capsid-associated DNA assay. The HepG2 
cells in a 6-well plate were transfected with the 2 plasmids plus HBV1.1c- 
respectively and lysed 5 days post-transfection. Part of the lysis of each sample 
was assayed as described above except that an RFP antibody was used for 
capsids assay. (E) HBV RNA assay. Northern blotting was used to detect the 
HBV RNA extracted from the HepG2 cells co-transfected with HBV1.1c- and 
the plasmids expressing different core proteins. (F) Core DNA assay. 
RFP-G4S47-HBc and RFP-G4S186-HBc were co-transfected with HBV1.1c- 
and intracellular core DNA was extracted 5 days after transfection respectively. 
Southern blotting was used to detect HBV DNA. SS DNA, single-strand DNA. 
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Table 
 
Primer Sequence (5’-3’) 
F1.1c- 
GATACCGCCTCAGCTCTGTATCGGTAAGCCTTAGAGTCTCCTG
AGCATTG 
R1.1c- CTCGTCGTCTAACAACAGTAGTCT 
FHBC 
CAATCTCGGGAATCTCAATGTTAGGAGATTAGGTTAAAGGTCT
TTGTAC 
RHBC 
GTACAAAGACCTTTAACCTAATCTCCTAACATTGAGATTCCCG
AGATTG 
F G12 
GGTGGCTTTGGGGCATGGACAGAACAACTTTGCCATATGGCCT
TTTTGGCTTAGACATCGACCCTTATAAAGAATT 
F4G 1 
GTGGCTTTGGGGCATGGACAGAACAACTTTACCCTATGGCCTA
TTCGGCCTTGACCGTA 
F4G2 ATTCGGCCTTGACCGTACTACCTTACCGTACGGATTGTTCGGTC
TAGATCGCACGACTC 
F4G3 CTAGATCGCACGACTCTTCCATACGGACTCTTCGGACTTGACA
GAACAACTTTGCCATA 
F G12 
GTGGCTTTGGGGCATGGACAGAACAACTTTACCCTATGGCCTA
TTCGGCCTT GACATCGACC CTTATAAAGA 
R2300 TCTATAAGCTGGAGGAGTGCGA 
FG4S12 
GCTTAGCCTTGGGTGGCTTTGGGGCATGGGTTCAGGAGGTGG
TGGATCTGGAGGAGGTGGATCTGACATCGACCCTTATAAAGA 
R1798 CCAATTTATGCCTACAGCCT 
F47gly 2 
GAGGTTCCGGTGGCGGCGGCAGTGGTGGTGGAGGCTCTGGTG
GTGGAGGCTCTGGAGGCGGAGGTTCAGGAGGTGGTGGATC 
F47gly 1 
TTGGGTGGCTTTGGGGCATGGGATCAGGCGGTGGCGGTTCAG
GAGGTGGTGGCTCAGGCGGAGGAGGTTCCGGTGGCGG 
Rc456 CTCGTCGTCTAACAACAGTAGTCT 
R BsmBI vect  GCTGACCGTCTCTCATGCCCCAAAGCCACCCAA 
F BsmBI vect TGCGTCCGTCTCCGACATCGACCCTTATAAAG 
F BsmBI1 TGCGTCCGTCTCCCATGGGATCAGGCGGTGGCGGTTC 
R BsmBI1  GCTGACCGTCTCACTGATCCACCTCCTCCAGATCCAC 
F BsmBI2 TGCGTCCGTCTCATCAGGCGGTGGCGGTTC 
R BsmBI2  GCTGACCGTCTCCTGTCAGATCCACCTCCTCCAGATC 
F BsmBIb TGCGTCCGTCTCAGGCAGCGGCGGTGGCGGTTC 
R BsmBIa GCTGACCGTCTCATGCCAGATCCACCTCCTCCAGA 
F BsmBIc TGCGTCCGTCTCCATCTGGATCAGGCGGTGGCGGTTC 
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R BsmBIb GCTGACCGTCTCTAGATCCACCTCCTCCAGA 
FGFP-HBC 
CCTCCAAGCTTAGCCTTGGGTGGCTTTGGGGCATGGTGAGCA
AGGGCGAGGAGCT 
RGFP-HBC   
TGAGCCACCACCTCCTGAACCGCCACCGCCTGATCCCTTGTAC
AGCTCGTCCATGC 
FRFP-HBC 
CCTCCAAGCTTAGCCTTGGGTGGCTTTGGGGCATGGCCTCCTC
CGAGGACGT 
RRFP-HBC   
TGAGCCACCACCTCCTGAACCGCCACCGCCTGATCCGTTATCT
AGATCCGGTGGA 
F1085 GCAGGCTTTCACTTTCTCGCCA
R1798 T7 TAATACGACTCACTATAGGGGACCAATTTATGCCTACAGCCT 
Table 1. Sequence of primers used to construct the plasmids or for RNA probe preparation. 
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